Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

Key opportunities in the rituximab biosimilars market include the launch of new biosimilar formulations, expansion of ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

(ORLANDO, Dec. 9, 2025) – In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more ...

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203 The article by Sharman et al entitled “Phase III Trial of ...

Six-year data show continuous zanubrutinib keeps CLL controlled longer than bendamustine-rituximab, including high-risk ...

Brukinsa showed superior PFS and ORR compared to Rituxan in CLL/SLL patients, with a 71% risk reduction in progression or death. Brukinsa's efficacy was consistent across various risk factors, ...

ORLANDO -- Patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) lived significantly longer without disease progression when treated with the Bruton's ...

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study Patients were randomly ...